Genomics of lung cancer in Indigenous people of North Queensland (Old ID 26764)

Principal Investigator

Cancer genomic profiling is a major determinant of chemotherapy selection for non-small cell lung cancer and is widely used internationally. Indigenous genomes carry ~10X more uncharacterised DNA sequence variation than people of European heritage. THHS is currently trialling the use of whole exome sequencing, instead of the existing 4 gene panel, to base choice of targeted therapies in lung cancer. This creates an opportunity to study whether the cancer-associated variation currently being used to select therapies is adequate, and if not, these data will form the foundation for an NHMRC funding application to identify improved markers.

11 Feb 2020 - 11 Feb 2021

N/A